BSJ-02-162

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameBSJ-02-162
Drug Alias NameBSJ-02-162
ClassificationSmall molecules > Heterocyclic drugsSmall molecules > Proteolysis-Targeting Chimera (PROTAC)
Mechanisms of ActionCyclin-dependent kinase 4 modulatorsCyclin-dependent kinase 6 modulatorsProteolysis
TargetsCyclin-dependent kinase 4Cyclin-dependent kinase 6
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A